Choroidal neovascularization
Therapeutic area
Ophthalmology
Rare disease
No
- Definition
- An eye disorder described by the growth of new blood vessels that originate from the choroid through a break in the Bruch membrane into the sub–retinal pigment epithelium (sub-RPE) or subretinal space. Choroidal neovascularization (CNV) is a major cause of visual loss.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Choroidal neovascularization
- Alternative names
- choroidal neovascularization
- Therapeutic area
- Ophthalmology
- All therapeutic areas
- Ophthalmology
- Severity
- Severe
- MONDO ID
- MONDO:0810000
- Parent condition
- MONDO:0005328
Related records
Broader conditions (6)
- Disease
- Disease by body system or component
- Disorder of orbital region
- Disorder of visual system
- Eye disorder
- Human disease
Trials (202)
- 20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD)
- A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD)
- A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
- A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
- A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMD
- A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Neovascular (Wet) Age-related Macular Degeneration
- A Dose Escalation Trial of an Intravitreal Injection of Sirna-027 in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)
- A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy
- A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy
- A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy
- A Population-based Study of Macular Choroidal Neovascularization in a Chinese Population
- A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)
- A Randomized, Double-masked, Multicenter, Controlled Study of Intravitreal KH902 in Patients With Neovascular AMD
- A Randomized, Double-masked, Multicenter,Sham-controlled, Safety and Efficacy Study of KH902 in Patients With Wet AMD
- A Research Study to Evaluate the Effects of Repeated Intravitreal Injections on Bacteria Around the Eye
- A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib
- A Safety Study in Healthy Volunteers to Evaluate Safety, How Fast the Drug is Absorbed, and the Side Effects of the Drug in Humans
- A Study Assessing the Safety and Efficacy of Multiple Intravitreal KH902 in Patients With CNV Due to AMD
- A Study Of Early Markers Of Choroidal Neovascularization
- A Study of the Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia.
Approved drugs (1)
Drugs in development (17)
- Adalimumab Phase 2
- Aflibercept Phase 3
- AGN-211745 Phase 2
- Bevacizumab Phase 3
- Brolucizumab Phase 3
- Daclizumab Phase 2
- Dexamethasone Phase 2
- Faricimab Phase 2
- Fosbretabulin disodium Phase 1
- Imatinib mesylate Phase 1
- Infliximab Phase 2
- Pegaptanib octasodium Phase 3
- Pegaptanib sodium Phase 2
- Sirolimus Phase 2
- TG100-801 Phase 2
- Triamcinolone acetonide Phase 3
- Verteporfin Phase 3